ArticleFrontiers in cellular and infection microbiology2022
Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study.
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Interventions to reduce the impact of post-tuberculosis lung disease: a scoping review of the literature.BMC pulmonary medicine · 2026Article
- Gut-Lung Microbiota Axis Shapes the Immune Microenvironment and Immunotherapeutic Response in Lung Cancer.International journal of biological sciences · 2026Review
- Pathogenesis of various pulmonary diseases by tuning immune response: insight from host-microbial crosstalk.Current research in microbial sciences · 2026Review
- Comparative microbiome profiling reveals unique signatures in multiple primary lung cancers.Translational cancer research · 2025Article
- Dysbiosis associated with enhanced microbial mobility across the respiratory tract in pulmonary tuberculosis patients.BMC microbiology · 2025Article
- Sputum microbiota profiles of patients with rifampicin-resistant tuberculosis during the intensive-phase treatment.BMC microbiology · 2025Article
- Dynamic changes of respiratory microbiota associated with treatment outcome in drug-sensitive and drug-resistant pulmonary tuberculosis.Annals of clinical microbiology and antimicrobials · 2024Article
- Association of symptomatic upper respiratory tract infections with the alteration of the oropharyngeal microbiome in a cohort of school children in Côte d'Ivoire.Frontiers in microbiology · 2024Article
- The uncharted territory of host-pathogen interaction in tuberculosis.Frontiers in immunology · 2024Review
- Effect of hyperglycemia on lung microbiota and treatment outcome in pulmonary tuberculosis: A scoping review.F1000Research · 2024Article
- The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression.Cells · 2023Review
- Sarcoidosis,Microorganisms · 2023Review
- Lung microbiome and origins of the respiratory diseases.Current research in immunology · 2023Review
- Clinical identification and microbiota analysis ofFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that lung microbiota can be recognized as one of the ecological determinants of various respiratory diseases. However, alterations in the lung microbiota and associated lung immunity in these respiratory diseases remain unclear. To compare the lung microbiota and lung immune profiles in common respiratory diseases, a total of 78 patients were enrolled in the present study, including 21 patients with primary pulmonary tuberculosis (PTB), eight patients with newly diagnosed lung cancer (LC), and 49 patients with community-acquired pneumonia (CAP). Bronchoalveolar lavage fluid (BALF) was collected for microbiota and cytokine analyses. With MiSeq sequencing system, increased bacterial alpha-diversity and richness were observed in patients with LC than in those with PTB and CAP. Linear discriminant analysis effect size revealed that CAP-associated pulmonary microbiota were significantly different between the PTB and LC groups. More key functionally different genera were found in the PTB and LC groups than in the CAP group. The interaction network revealed stronger positive and negative correlations among these genera in the LC group than in the other two groups. However, increased BALF cytokine profiles were observed in the PTB group than in the other two groups, while BALF cytokines were correlated with key functional bacteria. This comparative study provides evidence for the associations among altered lung microbiota, BALF inflammation, and different respiratory disorders, which provides insight into the possible roles and mechanisms of pulmonary microbiota in the progression of respiratory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.